News 
Market Data 
Discover
Replies to post #194578 on Biotech Values
Bass has been going after numerous pharmaceutical companies and their "BS patents." It's all part of an "activist short strategy" that Bass thinks will stop so-called pay-for-delay agreements that prevent lower-cost generic drug competitors from entering the market.
He has formed the Coalition for Affordable Drugs (CFAD), and the group has now filed 18 IPR petitions with the US Patent and Trademark Office challenging the validity of some drugmakers' patents while also betting against the company's stocks.
On February 10, Bass filed the IPR challenging the Acorda's patent for Ampyra, a treatment that helps improve walking in patients with multiple sclerosis. Then, on February 27, Bass filed another IPR, this time against the company's patent on "Sustained Release Aminopyridine Composition." Acorda's share price tumbled in the weeks that followed.
The denial of the two IPR petitions sets a worrying precedent for Bass. He has also targeted patents held by Biogen, Jazz Pharmaceuticals, Shire, and Celgene.
Celgene, which Bass has filed five IPRs against, recently filed a motion with the USPTO for sanctions on a claim of "abuse of process" by the Coalition for Affordable Drugs.
10/05/15 4:11 PM
On October 1, 2015, Acorda Therapeutics, Inc. entered into a settlement agreement with Actavis Laboratories FL, Inc. to resolve pending patent litigation brought by the Company against Actavis involving Ampyra (dalfampridine) Extended-Release Tablets. As a result of the settlement agreement, Actavis will be permitted to market a generic version of Ampyra in the United States at a specified date in 2027, or potentially earlier under certain circumstances.
AI
